To hear about similar clinical trials, please enter your email below
Trial Title:
Improving Patient-reported Outcomes After Lung Cancer Surgery With Mobile Internet Platform
NCT ID:
NCT06483295
Condition:
Lung Cancer
Conditions: Official terms:
Lung Neoplasms
Conditions: Keywords:
patient-reported outcomes
Internet
Study type:
Interventional
Study phase:
N/A
Overall status:
Recruiting
Study design:
Allocation:
Randomized
Intervention model:
Parallel Assignment
Primary purpose:
Supportive Care
Masking:
None (Open Label)
Intervention:
Intervention type:
Other
Intervention name:
Using mobile internet platforms for follow-up management of postoperative symptoms in lung cancer patients.
Description:
Using mobile internet platforms for follow-up management of postoperative symptoms in
lung cancer patients.
Arm group label:
Group A
Summary:
This study focuses on the significant impact of lung cancer in China, highlighted by its
high incidence and mortality rates, influenced by factors like aging populations,
smoking, and environmental issues. It emphasizes the importance of understanding the
duration, severity, and factors affecting post-surgery symptoms like pain and coughing in
patients. The research underlines the value of patient-reported outcomes (PROs) in
enhancing postoperative care and survival rates through improved symptom monitoring and
patient engagement. Utilizing internet technology, specifically a platform integrated
with WeChat, the study aims to improve patient management and follow-ups post-discharge.
The objective is to use mobile internet technology to build a high-quality prospective
database on postoperative lung cancer patient outcomes, analyzing factors affecting
postoperative discomfort and assessing the role of interactive platforms in improving
patient care.
Detailed description:
Lung cancer is the leading cause of cancer-related deaths worldwide. In China, it has
become the malignancy with the highest incidence and mortality rates, exacerbated by
aging populations, smoking, and environmental issues. Post-major lung surgery, patients
often experience reduced quality of life due to symptoms like pain and coughing. However,
the duration, severity, and factors influencing these symptoms during recovery are not
fully understood. Notably, recent attention has been given to the direct collection of
patient-reported outcomes (PROs) for subjective symptom monitoring and improving patient
care. Incorporating PRO monitoring in cancer patient follow-ups can reduce postoperative
discomfort, enhance treatment tolerance and adherence, detect early relapses, and improve
survival rates. Internet technology significantly expands information exchange frequency
and efficiency. Management platforms based on internet mobile applications can enhance
patient management compliance, enable intelligent follow-ups, and strengthen
doctor-patient interaction. The investigators' hospital intends to utilize its internet
hospital platform, integrated with WeChat (a Tencent application in China), for assisting
in-patient management and post-discharge surveillance through automated multimedia
material and PROs. WeChat, similar to Facebook and WhatsApp, is a multifunctional
messenger app with over a billion active monthly users in China, effectively using an
application already familiar to patients rather than introducing new ones.
This study aims to leverage mobile internet technology to transform traditional database
construction, enhance the efficiency and accuracy of prospective database information
collection, and establish a high-quality prospective database of postoperative lung
cancer patient-reported outcomes. This will facilitate the analysis of factors
influencing postoperative discomfort in patients and explore the role of interactive
mobile internet technology platforms in improving postoperative PROs, thereby elevating
the diagnostic and treatment standards in this field.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
1. Diagnosed with Stage I-III lung cancer and surgically resected at our centre.
2. Owns and uses a smartphone and can use WeChat.
3. Volunteer to participate in this study and sign an informed consent form.
Exclusion Criteria:
1. Received any non-surgical anti-tumour therapy (radiotherapy, chemotherapy, targeted
therapy or immunotherapy) for lung cancer during the follow-up period.
2. After enrolment, preoperative emergence of serious comorbidities (inability to
tolerate surgery or anaesthesia) that are not suitable for, or cannot be implemented
as planned, in the study's treatment regimen.
3. After admission, the patient's condition changes and the need to change from
elective surgery to emergency surgery is confirmed by the doctor in charge.
4. At any stage after entering the study, the patient voluntarily requests to withdraw
or discontinue treatment due to personal reasons.
Gender:
All
Minimum age:
18 Years
Maximum age:
80 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
Zuodong Song
Address:
City:
Shanghai
Zip:
200030
Country:
China
Status:
Recruiting
Contact:
Last name:
Zuodong Song
Email:
szd1990@hotmail.com
Start date:
February 1, 2023
Completion date:
December 31, 2026
Lead sponsor:
Agency:
Shanghai Chest Hospital
Agency class:
Other
Source:
Shanghai Chest Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06483295